Ovid Therapeutics Inc.
OVID · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $6 | $0 | $0 |
| % Growth | -97.9% | 4,724.6% | 71.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $6 | $0 | $0 |
| % Margin | 87.1% | 100% | 100% | 100% |
| R&D Expenses | $6 | $6 | $7 | $6 |
| G&A Expenses | $0 | $5 | $6 | $7 |
| SG&A Expenses | $7 | $5 | $6 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$2 |
| Operating Expenses | $13 | $11 | $13 | $11 |
| Operating Income | -$13 | -$5 | -$13 | -$11 |
| % Margin | -9,487.1% | -80.9% | -9,653.8% | -14,107.9% |
| Other Income/Exp. Net | $0 | $0 | $2 | $1 |
| Pre-Tax Income | -$12 | -$5 | -$10 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12 | -$5 | -$10 | -$9 |
| % Margin | -9,210.6% | -74.7% | -7,873.1% | -12,175% |
| EPS | -0.17 | -0.066 | -0.14 | -0.13 |
| % Growth | -158% | 52.9% | -7.7% | – |
| EPS Diluted | -0.17 | -0.066 | -0.14 | -0.13 |
| Weighted Avg Shares Out | 71 | 71 | 71 | 71 |
| Weighted Avg Shares Out Dil | 71 | 71 | 71 | 71 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$12 | -$5 | -$12 | -$11 |
| % Margin | -9,197.7% | -79.3% | -9,545.4% | -14,160.5% |